This article is more than 5 years old. Information may no longer be current.
Dermatitis, psoriasis developments most read Healio Dermatology articles of week
Click Here to Manage Email Alerts
Developments regarding dermatitis and psoriasis were the most read articles during the past week in Healio Dermatology.
U.S. Federal Trade Commission action regarding Actavis’ pending acquisition of Allergan also was among the top read stories:
Seven recent developments regarding dermatitis
Recent developments involving dermatitis include the use of vitamin D supplementation to improve winter-related symptoms in children and the U.S. Food and Drug Administration granting breakthrough therapy designation to dupilumab for adults with moderate-to-severe atopic dermatitis. Read more
Seven recent developments in psoriasis
Recent developments involving psoriasis include the use of tonsillectomy and anti-tumor necrosis factor-alpha agents to help patients with psoriasis, as well as an association between psoriasis and uncontrolled hypertension. Read more
FDA approves Galderma's Soolantra Cream for treatment of rosacea lesions
Galderma Laboratories announced that the FDA has approved Soolantra Cream for once-daily, topical treatment of inflammatory rosacea lesions, according to a press release.
Linda Stein Gold
“While some rosacea treatments … may take more than 4 weeks to show effect, Soolantra Cream may provide initial results as early as week 2,” Linda Stein Gold, MD, a Galderma consultant and clinical investigator for the phase 3 studies of Soolantra Cream (ivermectin cream, 1%), said in a press release. Read more
FDA approves Suneva's Bellafill dermal filler for treatment of acne scars
Suneva Medical announced that the FDA has approved its dermal filler, Bellafill, for treating acne scars.
Bellafill is designed to add volume to the skin to smooth out pitted acne scars through an in-office injection procedure with little-to-no downtime, according to a company press release. Read more
Early termination of HSR Act waiting period granted for Actavis' acquisition of Allergan
Actavis and Allergan have announced that the U.S. Federal Trade Commission has allowed early termination of the Hart-Scott-Rodino Antitrust Improvement Act of 1976 waiting period with respect to Actavis’ pending acquisition of Allergan.
The companies have set the close of business on Jan. 22 as the record date for determining shareholders that will be allowed to vote at their respective special meetings of shareholders, which will be held in connection with the pending acquisition, according to a press release. Read more